Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905563 | 0.79 | KDM4E (0.32) | KDM4ERAB9APOLB | |
| SCHEMBL21375246 | 0.79 | KDM4E (0.32) | KDM4ERAB9APOLB | |
| SCHEMBL823816 | 0.74 | TSHR (0.33) | KDM4ERAB9APOLBDGAT1 | |
| SCHEMBL7604249 | 0.74 | APLNR (0.41) | — | |
| SCHEMBL14595286 | 0.74 | NUDT1 (0.38) | KDM4ERAB9ANPC1 | |
| SCHEMBL10864216 | 0.73 | ALDH1A1 (0.58) | KDM4ERAB9APOLBNPC1 | |
| SCHEMBL10105664 | 0.72 | CNR1 (0.31) | — | |
| SCHEMBL22663608 | 0.72 | — | — | |
| SCHEMBL21695568 | 0.72 | — | — | |
| SCHEMBL10220412 | 0.72 | CYP19A1 (0.31) | RAB9ANPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0139477-A2 | Process for preparing 5-substituted pyrimidines | ELI LILLY AND COMPANY (US) | 1985-05-02 | — | — | EP | claimed |
| EP-4615836-A1 | INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE METHODS OF USE THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102924-A1 | INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE METHODS OF USE THEREOF | FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-115010764-B | Platinum-aza-carbene complex and synthetic method and application thereof | 太原理工大学 | 2024-03-29 | — | — | CN | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-2726490-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-04-29 | — | — | EP | disclosed |
| WO-2015000546-A1 | POLYCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013000531-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2013-01-03 | — | — | WO | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| EP-2379513-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010078408-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| CN-1886378-A | 1,4-disubstituted isoquinilone derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2006-12-27 | — | — | CN | disclosed |
| EP-0139477-A2 | Process for preparing 5-substituted pyrimidines | ELI LILLY AND COMPANY (US) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 2722/4885RAB9A 614/4885POLB 2646/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KDM4E 4157/4885RAB9A 277/4885POLB 3123/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | KDM4E 1491/4885RAB9A 598/4885POLB 1166/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KDM4E 4157/4885RAB9A 277/4885POLB 3123/4885 |
| US-11917901-B2 | Metal complexes | MCOLN2, MCOLN1, AP1M1 | KDM4E 4260/4885RAB9A 2962/4885POLB 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.